Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAL: Birtamimab in AL amyloidosis
NCT02312206Phase 3Terminated
- Sponsor
- Prothena Corporation
- Start
- Feb 2015
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing NEOD001 + SoC with Placebo + SoC (2 arms). Primary endpoint: Time to Composite of All-cause Mortality or Cardiac Hospitalization up to 32 months. Started Feb 2015; status: terminated.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT02312206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02312206.